Drug
Risdiplam
Risdiplam: highest development phase Post-Market, developed by Roche. 2 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Roche
Trials
| Drug | Phase | Indication |
|---|---|---|
| Risdiplam NCT05861986 | Post-Market | Muscular Atrophy, Spinal |
| Risdiplam NCT03920865 | Phase 1 | Muscular Atrophy, Spinal |
Latest
No recent events.
Follow Risdiplam on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.